Texas is currently home to 4873 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Human-Machine System for the H2 Lower Limb Exoskeleton
Recruiting
This research study will investigate the use of smart lower limb robotic exoskeleton (developed by the CSIC, Spain) in rehabilitation after stroke. It will compare robotic-assisted rehabilitation with supervised motor practice. Additionally, it will also examine the use of noninvasive scalp electroencephalography (EEG) to learn specific brain wave patterns associated with learning to walk on the powered lower limb exoskeleton. The findings will be used to understand human-robot interaction and t... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/26/2024
Locations: TIRR Memorial Hermann Hospital, Houston, Texas
Conditions: Stroke, Hemiparesis
Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
Recruiting
Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/25/2024
Locations: Austin Plastic Surgeon, Austin, Texas
Conditions: Post Procedural Erythema
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Recruiting
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: Mary Crowley Cancer Center - Clinic, Dallas, Texas
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Recruiting
Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction. This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Various dosing reg... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: MuSK Myasthenia Gravis
Chimeric Antigen Receptor T-cells for the Treatment of AML Expressing CLL-1 Antigen
Recruiting
Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and T cells with the hope that they will work together. T cells (also called T lymphocytes) are special infection-fighting blood cells that can kill other cells including tumor cells. Antibodies are ty... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
10/25/2024
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Acute Myeloid Leukemia
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Recruiting
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Recruiting
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Uveal Melanoma
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recruiting
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mor... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/24/2024
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Carcinoma, Hepatocellular, Cirrhosis
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Recruiting
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/24/2024
Locations: Trio Clinical Trials, LLC., Houston, Texas
Conditions: Peanut Allergy
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Renovatio Clinical Research, El Paso, Texas
Conditions: Multiple Myeloma
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Recruiting
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
Recruiting
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/23/2024
Locations: ICON Early Phase, LLC, San Antonio, Texas
Conditions: RSV Infection, QTc Interval